Back to Trials
NCT06776783PHASE3Recruiting

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

Aerogen Pharma Limited

Start Date

9/24/2025

Completion Date

5/1/2029

Summary

This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: 1. Inborn at the study site's hospital (i.e., not transferred from another hospital following delivery) 2. Gestational age at birth of 26 through 33 weeks PMA 3. Birth weight appropriate for gestational age (AGA, weight 3rd to 97th percentile on Fenton Growth Curve) 4. Birth weight ≤ 2000 grams 5. Post-natal age 1 to 24 hours at randomization 6. On nCPAP or NIV for at least 30 minutes with RSS = 1.4 - 2.0 to maintain SpO2 90-95% at randomization. RSS is calculated as (nCPAP cm H2O) × (FiO2) or as (NIV mean airway pressure cm H2O) × (FiO2). 7. FiO2 ≥ 0.24 at randomization 8. nCPAP or mPaw ≥ 6 cm H2O at randomization 9. Chest radiograph (CXR) or lung ultrasound compatible with RDS prior to randomization Exclusion Criteria: 1. On SiPAP®, RAM® cannula, or high flow nasal cannula (HFNC) (\> 2 liters per minute \[LPM\]) at the time of randomization 2. Prior instillation of surfactant 3. Premature rupture of membranes (PROM) occurring \> 14 days before birth 4. Significant congenital/chromosomal anomaly (e.g., Pierre Robin syndrome, clinically significant congenital heart disease, or trisomy) 5. Pneumothorax 6. Other etiologies of respiratory distress 7. Enrollment in another interventional study with similar efficacy endpoints 8. Apgar score at 5 min of 0-3 9. Prior cardiopulmonary resuscitation (CPR) or epinephrine 10. Base Deficit \> 15 mEq/L on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. Note that arterial blood gas is not required prior to randomization. 11. Partial pressure of carbon dioxide (PaCO2) \> 65 mmHg on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. 12. Triplet or higher order multiple birth

Interventions

COMBINATION_PRODUCT

APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)

OTHER

Control

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Respiratory Distress SyndromePre-term Infants

Locations

University of Arkansas for Medical Sciences

Little Rock, Arkansas 72205

United States

Jacobs Medical Center

La Jolla, California 92037

United States

UF Health Jacksonville

Jacksonville, Florida 32209

United States

Advent Health

Orlando, Florida 32803

United States

Memorial Hospital of South Bend

South Bend, Indiana 46601

United States

Goryeb Children's Hospital

Morristown, New Jersey 07960

United States

The Trustees of Columbia University in the City of New York

New York, New York 10032

United States

Montefiore Medical Center

The Bronx, New York 10461

United States

Maria Farreri Children's Hospital

Valhalla, New York 10595

United States

Christus Children's Hospital

San Antonio, Texas 78207

United States

University of Virginia School of Medicine

Charlottesville, Virginia 22903

United States

WVU Medicine Children's Hospital

Morgantown, West Virginia 26506

United States